id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-025481-ljs80v45	Hu, Jianhua	COVID-19 patients with hypertension have more severity condition, and ACEI/ARB treatment have no infulence on the clinical severity and outcome	2020-05-28		.txt	text/plain	1016	67	54	Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2); Coronavirus disease 2019 (COVID-19); Hypertention; Angiotensin-converting enzyme inhibitor (ACEI); Angiotensin receptor blocker (ARB); Outcome A number of pneumonia cases of unknown causes have emerged in Wuhan, Hubei, China since December 2019. Whether patients with hypertension who undergo angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) therapy are more likely to suffer SARS-CoV-2 infection and whether ACEI/ARB therapy would have an influence on the clinical outcomes of patients with COVID-19 are controversy. Compared with patients without hypertension, patients with hypertension had a higher incidence of acute respiratory distress syndrome(ARDS) (24.16% vs 6.67%, P=0.000), were more likely to use glucocorticoids (31.54% vs 12.79%, P=0.000), antibiotic (50.33% vs 39.32%, P=0.013), and intravenous immune globulin therapy (21.48% vs 6.67%, P=0.000) and more likely to need mechanical ventilation (14.77% vs 2.04%, P=0.000) and intensive care unit (ICU) admission (16.11% vs 2.31%, P=0.000), extracorporeal membrane oxygenation (ECMO) (4.03% vs 0.82%, P=0.007) and continuous renal replacement therapy (CRRT) (2.01%vs 0.14%, P=0.016) therapy.	./cache/cord-025481-ljs80v45.txt	./txt/cord-025481-ljs80v45.txt